IPSC
Century Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$2.19-2.67%
Price as of Jul 20, 2026
IPSC financials
Century Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $109.2M | $6.6M | $2.2M | $5.2M |
| Cost of revenue | $13.1M | $0.00 | $0.00 | $0.00 |
| Gross profit | $96.1M | $6.6M | $2.2M | $5.2M |
| Operating expenses | $111.1M | $144.7M | $148.8M | $139.0M |
| Operating income | -$15.0M | -$138.1M | -$146.5M | -$133.8M |
| Net income | -$9.6M | -$126.6M | -$136.7M | -$130.9M |
| EBITDA | $3.5M | -$111.5M | -$121.2M | -$121.2M |
| Basic EPS | $-0.11 | $-1.61 | $-2.30 | $-2.27 |
| Diluted EPS | $-0.11 | $-1.61 | $-2.30 | $-2.27 |
| Balance sheet | ||||
| Cash & equivalents | $61.9M | $58.4M | $47.3M | $84.3M |
| Total assets | $223.7M | $353.2M | $360.7M | $486.5M |
| Total liabilities | $64.8M | $191.9M | $175.9M | $183.8M |
| Stockholders’ equity | $158.9M | $161.4M | $184.8M | $302.7M |
| Total debt | $43.6M | $53.8M | $48.2M | $49.4M |
| Net debt | -$18.3M | -$4.6M | $847.0K | -$34.9M |
| Cash flow | ||||
| Operating cash flow | -$103.9M | -$110.1M | -$88.3M | $14.1M |
| Capital expenditure | -$848.0K | -$154.0K | -$13.7M | -$30.6M |
| Free cash flow | -$104.7M | -$110.3M | -$102.1M | -$16.6M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |